Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Perfectha Derm Lidocaine is a cross-linked hyaluronic acid-based injectable dermal filler developed by Sinclair Pharma. It is formulated with 20 mg/mL of cross-linked sodium hyaluronate and 0.3% lidocaine hydrochloride, which serves as a local anesthetic to enhance patient comfort during administration. As a dermal filler, it is primarily indicated for the correction of medium to deep facial wrinkles and skin depressions, such as nasolabial folds and marionette lines, as well as for lip volume augmentation and contour definition. The gel works by integrating into the extracellular matrix, where the hyaluronic acid binds water to restore tissue structure and provide physical volumization. It is CE-marked as a medical device and is typically administered via intradermal injection by healthcare professionals, with effects reported to last between 9 and 12 months.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Perfectha Derm Lidocaine.